AI
Thursday, December 12, 2013 7:37:32 PM
Nov2013: Stephen Worsley joins Peregrine as VP of Bus.Dev.
“Mr. Worsley has executed numerous business transactions in the antibody drug market; most notably with the companies Abgenix and Raven Biotechnology where he was responsible for out-licensing each of the company’s clinical-level assets. These transactions included agreements with numerous major pharmaceutical and large biotechnology companies for the licensing of early & late stage clinical products and the formation of joint ventures and other strategically important business development initiatives.”
= = = = = = = = = = = = = = =
12-10-13 10Q PR & Qtly CC Transcript - http://tinyurl.com/mw776mk
CEO STEVE KING – OPENING COMMENTS:
On the corporate development front, we are pleased to announce the addition of Steve Worsley as VP of Business Development. Steve comes to us with a great track record in business development, particularly in the monoclonal antibody space, and will be briefly introduced.
- - - - -
SK Intro’ing Mr. Steve Worsley: Today, we also announced that Mr. Stephen Worsley has joined Peregrine as VP of Business Development, as a member of our executive team. Steve brings some over 15 years of business development experience within the biotechnology & pharmaceutical worlds, and we expect his addition will significantly augment and expand the ongoing business development discussions around our bavituximab, the broader PS-targeting, and Cotara platforms. I will now turn the call over to Steve for a brief introduction.
[ http://www.peregrineinc.com/about-us/management-team.html ]
- - - - - - - - - -
STEPHEN WORSLEY (VP/Business Dev.)
Thanks, Steve. It's a pleasure to be here. As background, prior to joining Peregrine, I was Chief Business Officer at Centrose Pharmaceuticals, an antibody drug conjugate company, that is developing new ADC drugs for cancer. Prior to that, I was VP of Business Dev. at Intrexon, as well as numerous other antibody-focused firms. Leading the business development effort at Peregrine with respect to bavituximab will mark the 6th clinical-level drug licensing program that I have led and closed. Of those deals, of those deals, 2 opportunities led to an acquisition by a larger partner. In the case of the Vectibix deal, it was a key element in the buyout of Abgenix by Amgen for $2.3B. I also led the licensing of RAV12 & B7-H3 antibodies for Raven Biotechnologies, which evolved into an acquisition of Raven by MacroGenics in 2008. All in all, I've licensing antibodies in the oncology space for the better part of the last 15 years and very much look forward to executing the business development strategy for Peregrine, especially as our efforts to get to a Phase III up and running, as well as a number of proof-of-concept studies will add even more value to the bavituximab program.
= = = = = = = = = = = = = = = = = = = = = = = =
12-10-13 PR: Peregrine Pharmaceuticals Reports Q2FY’14 Financial Results and Recent Developments
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=813049
CORPORATE
Today Peregrine announced the addition of Mr. Stephen Worsley as Vice President of Business Development. Mr. Worsley joins the Executive team bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Most recently he was Chief Business Officer at Centrose Pharmaceuticals. Prior to that he held the position of VP of Business Development at Intrexon Inc., Zosano Pharma Inc., (a spin out of Johnson & Johnson) and Raven Biotechnologies, Inc. (acquired by MacroGenics). In addition, he was Director of Business Development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen received his MBA in finance from the University of Washington and his Bachelor of Science in international economics and finance from the University of Utah.
= = = = =LinkedIN 12-12-13:
Stephen Worsley – VP, Business Development, Peregrine Pharmaceuticals (beg. 11-2013)
http://www.linkedin.com/pub/stephen-worsley/26/b35/271
Current:
• VP, Business Development, Peregrine Pharmaceuticals
• Board Advisor, OpenPlacement (a Rock Health graduate company)
PAST:
• CBO/VP Sales & Licensing, Centrose Pharmaceutical 2011-13
• VP, Business Dev., Intrexon Corp. 2010-11
• VP, Business Dev., Zosano Pharma (Johnson & Johnson spinout) 2008-10)
• VP, Business Dev., Raven Biotechnologies (acquired by MacroGenics) 2003-08
• Dir. of Business Dev., Abgenix (acq. by AMGEN) 1999-2003
• Dir. of Business Dev., Tripos Drug Discovery 1996-99
• Dir. of Business Dev., OHM Technologies (acq. by Carlyle Group) 1990-96
• Marketing Manager, Symbion Cardiovascular Systems 1986-88
Education:
• Univ. of Utah - BS, Economics (chem-minor) 1986
• Univ. of Washington – MBA, Finance 1990
• Johns Hopkins Univ. - MS, Biotechnology- (In process)
MGT. PROFILE ON PEREGRINE’S WEBSITE:
STEPHEN T. WORSLEY – VP, BUSINESS DEVELOPMENT
Stephen Worsley was appointed VP of Business Development in November 2013, bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Prior to joining Peregrine he was Chief Business Officer at Centrose Pharmaceuticals and prior to that he held the position of VP of Business Development at Intrexon, Zosano Pharma, (a spin out of Johnson & Johnson) and Raven Biotechnologies (acquired by MacroGenics). In addition, he was Director of Business Development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen holds an MBA in finance from the Univ. of Washington and a Bachelor of Science in international economics and finance from the Univ. of Utah.
http://www.peregrineinc.com/about-us/management-team.html
= = = = = = = = = = = = = =
PRIOR PROFILE ON CENTROSE WEBSITE:
Mr. Worsley is the Chief Business Officer of Centrose and bringing over 25 years of antibody industry experience to the Company. Mr. Worsley has executed numerous business transactions in the antibody drug market; most notably with the companies Abgenix and Raven Biotechnology where he was responsible for out-licensing each of the company’s clinical-level assets. These transactions included agreements with numerous major pharmaceutical and large biotechnology companies for the licensing of early and late stage clinical products and the formation of joint ventures and other strategically important business development initiatives. Mr. Worsley led the out-licensing of Vectibix, the first fully human monoclonal antibody specific to the epidermal growth factor receptor (HER1). Vectibix is now manufactured and marketed by Amgen for the treatment of colorectal cancer. Most recently, Mr. Worsley was VP of Business Dev. with Intrexon, a privately held early-stage biotechnology company focused on drug development. Mr. Worsley graduated and received his MBA from University of Washington and graduated and received his BA degree cum laude in intl. economics/finance from University of Utah.
http://centrosepharma.com
“Mr. Worsley has executed numerous business transactions in the antibody drug market; most notably with the companies Abgenix and Raven Biotechnology where he was responsible for out-licensing each of the company’s clinical-level assets. These transactions included agreements with numerous major pharmaceutical and large biotechnology companies for the licensing of early & late stage clinical products and the formation of joint ventures and other strategically important business development initiatives.”
= = = = = = = = = = = = = = =
12-10-13 10Q PR & Qtly CC Transcript - http://tinyurl.com/mw776mk
CEO STEVE KING – OPENING COMMENTS:
On the corporate development front, we are pleased to announce the addition of Steve Worsley as VP of Business Development. Steve comes to us with a great track record in business development, particularly in the monoclonal antibody space, and will be briefly introduced.
- - - - -
SK Intro’ing Mr. Steve Worsley: Today, we also announced that Mr. Stephen Worsley has joined Peregrine as VP of Business Development, as a member of our executive team. Steve brings some over 15 years of business development experience within the biotechnology & pharmaceutical worlds, and we expect his addition will significantly augment and expand the ongoing business development discussions around our bavituximab, the broader PS-targeting, and Cotara platforms. I will now turn the call over to Steve for a brief introduction.
[ http://www.peregrineinc.com/about-us/management-team.html ]
- - - - - - - - - -
STEPHEN WORSLEY (VP/Business Dev.)
Thanks, Steve. It's a pleasure to be here. As background, prior to joining Peregrine, I was Chief Business Officer at Centrose Pharmaceuticals, an antibody drug conjugate company, that is developing new ADC drugs for cancer. Prior to that, I was VP of Business Dev. at Intrexon, as well as numerous other antibody-focused firms. Leading the business development effort at Peregrine with respect to bavituximab will mark the 6th clinical-level drug licensing program that I have led and closed. Of those deals, of those deals, 2 opportunities led to an acquisition by a larger partner. In the case of the Vectibix deal, it was a key element in the buyout of Abgenix by Amgen for $2.3B. I also led the licensing of RAV12 & B7-H3 antibodies for Raven Biotechnologies, which evolved into an acquisition of Raven by MacroGenics in 2008. All in all, I've licensing antibodies in the oncology space for the better part of the last 15 years and very much look forward to executing the business development strategy for Peregrine, especially as our efforts to get to a Phase III up and running, as well as a number of proof-of-concept studies will add even more value to the bavituximab program.
= = = = = = = = = = = = = = = = = = = = = = = =
12-10-13 PR: Peregrine Pharmaceuticals Reports Q2FY’14 Financial Results and Recent Developments
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=813049
CORPORATE
Today Peregrine announced the addition of Mr. Stephen Worsley as Vice President of Business Development. Mr. Worsley joins the Executive team bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Most recently he was Chief Business Officer at Centrose Pharmaceuticals. Prior to that he held the position of VP of Business Development at Intrexon Inc., Zosano Pharma Inc., (a spin out of Johnson & Johnson) and Raven Biotechnologies, Inc. (acquired by MacroGenics). In addition, he was Director of Business Development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen received his MBA in finance from the University of Washington and his Bachelor of Science in international economics and finance from the University of Utah.
= = = = =LinkedIN 12-12-13:
Stephen Worsley – VP, Business Development, Peregrine Pharmaceuticals (beg. 11-2013)
http://www.linkedin.com/pub/stephen-worsley/26/b35/271
Current:
• VP, Business Development, Peregrine Pharmaceuticals
• Board Advisor, OpenPlacement (a Rock Health graduate company)
PAST:
• CBO/VP Sales & Licensing, Centrose Pharmaceutical 2011-13
• VP, Business Dev., Intrexon Corp. 2010-11
• VP, Business Dev., Zosano Pharma (Johnson & Johnson spinout) 2008-10)
• VP, Business Dev., Raven Biotechnologies (acquired by MacroGenics) 2003-08
• Dir. of Business Dev., Abgenix (acq. by AMGEN) 1999-2003
• Dir. of Business Dev., Tripos Drug Discovery 1996-99
• Dir. of Business Dev., OHM Technologies (acq. by Carlyle Group) 1990-96
• Marketing Manager, Symbion Cardiovascular Systems 1986-88
Education:
• Univ. of Utah - BS, Economics (chem-minor) 1986
• Univ. of Washington – MBA, Finance 1990
• Johns Hopkins Univ. - MS, Biotechnology- (In process)
MGT. PROFILE ON PEREGRINE’S WEBSITE:
STEPHEN T. WORSLEY – VP, BUSINESS DEVELOPMENT
Stephen Worsley was appointed VP of Business Development in November 2013, bringing with him over 25 years in the biotechnology industry with 16 of those in business development. Prior to joining Peregrine he was Chief Business Officer at Centrose Pharmaceuticals and prior to that he held the position of VP of Business Development at Intrexon, Zosano Pharma, (a spin out of Johnson & Johnson) and Raven Biotechnologies (acquired by MacroGenics). In addition, he was Director of Business Development at Abgenix (acquired by Amgen), Tripos Drug Discovery, and OHM Technologies (acquired by Carlyle Group). Stephen holds an MBA in finance from the Univ. of Washington and a Bachelor of Science in international economics and finance from the Univ. of Utah.
http://www.peregrineinc.com/about-us/management-team.html
= = = = = = = = = = = = = =
PRIOR PROFILE ON CENTROSE WEBSITE:
Mr. Worsley is the Chief Business Officer of Centrose and bringing over 25 years of antibody industry experience to the Company. Mr. Worsley has executed numerous business transactions in the antibody drug market; most notably with the companies Abgenix and Raven Biotechnology where he was responsible for out-licensing each of the company’s clinical-level assets. These transactions included agreements with numerous major pharmaceutical and large biotechnology companies for the licensing of early and late stage clinical products and the formation of joint ventures and other strategically important business development initiatives. Mr. Worsley led the out-licensing of Vectibix, the first fully human monoclonal antibody specific to the epidermal growth factor receptor (HER1). Vectibix is now manufactured and marketed by Amgen for the treatment of colorectal cancer. Most recently, Mr. Worsley was VP of Business Dev. with Intrexon, a privately held early-stage biotechnology company focused on drug development. Mr. Worsley graduated and received his MBA from University of Washington and graduated and received his BA degree cum laude in intl. economics/finance from University of Utah.
http://centrosepharma.com
